Previous 10 | Next 10 |
2023-05-04 17:22:29 ET Assembly Biosciences press release ( NASDAQ: ASMB ): Q1 GAAP EPS of -$0.37. Cash, cash equivalents and marketable securities were $73.0 million as of March 31, 2023, compared to $91.6 million as of December 31, 2022. For further details see: ...
Herpesvirus candidate ABI-5366 progressing towards IND and planned to enter the clinic in the first half of 2024 Additional development candidate nomination anticipated in 2023 Multiple abstracts accepted for presentation at EASL 2023 in June SOUTH SAN FRANCISCO, Calif.,...
Phase 1a clinical data for remaining 200 mg multiple dose cohort for ABI-4334 continue to demonstrate encouraging clinical profile with strong projected activity against both viral replication and cccDNA formation Assembly Bio will evaluate partnering options for its core inhibitor port...
2023-03-22 16:58:28 ET Assembly Biosciences press release ( NASDAQ: ASMB ): FY GAAP EPS of -$1.92 in-line. Cash, cash equivalents and marketable securities were $91.6 million as of December 31, 2022, compared to $108.7 million as of September 30, 2022, and $174.6 million a...
Prioritization of core inhibitor candidate ABI-4334 and pausing of core inhibitor candidate ABI-H3733 based on data to date from ongoing clinical Phase 1 studies of both candidates and chronic toxicology observation for ABI-H3733 Phase 1a complete clinical data for all ABI-4334 dose cohor...
−ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Assembly Bioscience...
In initial ABI-H3733 cohort of 50 mg in 28-day Phase 1b study, six of eight HBV patients on treatment reached lower limit of quantification for HBV DNA by day 21 and patients showed a mean reduction of 3.1 logs in plasma HBV DNA Initial ABI-4334 Phase 1a single-dose 30 mg cohort demon...
Healthy volunteer study will inform development of 4334 for treatment of hepatitis B virus SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational t...
Assembly Biosciences press release ( NASDAQ: ASMB ): Q3 GAAP EPS of -$0.48 beats by $0.06 . Cash, cash equivalents and marketable securities were $108.7 million as of September 30, 2022, compared to $128.6 million as of June 30, 2022. The company’s cash pos...
Phase 1a Trial of Next-Generation Core Inhibitor, ABI-4334, Now Underway Following Clinical Trial Application (CTA) Clearance SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing i...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...